|Bid||164.10 x 0|
|Ask||164.13 x 0|
|Day's range||163.16 - 167.00|
|52-week range||119.01 - 167.66|
|PE ratio (TTM)||46.15|
|Forward dividend & yield||2.01 (1.21%)|
|1y target est||N/A|
Biotechnology company CSL Limited (ASX:CSL) has had a stellar run after releasing its half yearly earnings report on February 14. After closing Friday's trading session at $165.57, the company's valuation of around 36 times projected FY18 earnings appears to be getting stretched. Is it time for investors to take profits?
Natixis has bought stakes in three M&A boutiques in the UK, China and France that build on the French investment bank’s “multi-boutique” approach to advising companies on deals. The bank, which is majority-owned ...
The CSL Limited (ASX:CSL) share price rose 5% to $148.88 after the company reported a 35% increase in profit this morning.
The CSL Limited (ASX:CSL) share price climbed 1.55% to $149.84 this week, despite the company not releasing any announcements to the market.
According to Bloomberg, top strategists at Goldman Sachs are predicting a market correction in global equities of between 10% and 20% in the coming months. What does this mean for your portfolio?
The healthcare sector has rallied ahead of the market and this reporting season will determine which stocks can keep outperforming. Here are two that are tipped to beat market expectations.